HIGHLIGHTS
- who: JungJin Oh and colleagues from the Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea have published the research work: Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects, in the Journal: Pharmaceutics 2023, 549 of /2023/
- what: This study aimed to examine the PK and PD interactions between aspirin and fexuprazan. Based on the exploratory and descriptive characteristics of the study aim, the calculation of study power was not considered to determine the sample size. Among . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.